404 related articles for article (PubMed ID: 19175829)
41. NKG2D regulates production of soluble TRAIL by ex vivo expanded human γδ T cells.
Dokouhaki P; Schuh NW; Joe B; Allen CA; Der SD; Tsao MS; Zhang L
Eur J Immunol; 2013 Dec; 43(12):3175-82. PubMed ID: 24019170
[TBL] [Abstract][Full Text] [Related]
42. [A study of intercellular adhesion molecule-1 (ICAM-1) in cervical cancer].
Okamoto Y; Tsurunaga T; Ueda M; Yamada T; Ueki M; Sugimoto O
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Jun; 45(6):566-70. PubMed ID: 8100249
[TBL] [Abstract][Full Text] [Related]
43. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis.
Hiraoka N; Yamazaki-Itoh R; Ino Y; Mizuguchi Y; Yamada T; Hirohashi S; Kanai Y
Gastroenterology; 2011 Jan; 140(1):310-21. PubMed ID: 20955708
[TBL] [Abstract][Full Text] [Related]
44. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules.
Weijtens ME; Willemsen RA; van Krimpen BA; Bolhuis RL
Int J Cancer; 1998 Jul; 77(2):181-7. PubMed ID: 9650549
[TBL] [Abstract][Full Text] [Related]
45. Intercellular adhesion molecule-3 is the predominant co-stimulatory ligand for leukocyte function antigen-1 on human blood dendritic cells.
Starling GC; McLellan AD; Egner W; Sorg RV; Fawcett J; Simmons DL; Hart DN
Eur J Immunol; 1995 Sep; 25(9):2528-32. PubMed ID: 7589121
[TBL] [Abstract][Full Text] [Related]
46. Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells.
Gwin JL; Gercel-Taylor C; Taylor DD; Eisenberg B
J Surg Res; 1996 Jan; 60(1):129-36. PubMed ID: 8592403
[TBL] [Abstract][Full Text] [Related]
47. [LAK sensitivity of human pancreas carcinoma cell lines].
Sugiura H
Hokkaido Igaku Zasshi; 1993 Nov; 68(6):921-34. PubMed ID: 7906667
[TBL] [Abstract][Full Text] [Related]
48. Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis.
Robertson MJ; Caligiuri MA; Manley TJ; Levine H; Ritz J
J Immunol; 1990 Nov; 145(10):3194-201. PubMed ID: 1700001
[TBL] [Abstract][Full Text] [Related]
49. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells.
Shojaei H; Oberg HH; Juricke M; Marischen L; Kunz M; Mundhenke C; Gieseler F; Kabelitz D; Wesch D
Cancer Res; 2009 Nov; 69(22):8710-7. PubMed ID: 19887600
[TBL] [Abstract][Full Text] [Related]
50. At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.
Norell H; Moretta A; Silva-Santos B; Moretta L
J Leukoc Biol; 2013 Dec; 94(6):1123-39. PubMed ID: 24108703
[TBL] [Abstract][Full Text] [Related]
51. CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.
Peipp M; Wesch D; Oberg HH; Lutz S; Muskulus A; van de Winkel JGJ; Parren PWHI; Burger R; Humpe A; Kabelitz D; Gramatzki M; Kellner C
Scand J Immunol; 2017 Oct; 86(4):196-206. PubMed ID: 28708284
[TBL] [Abstract][Full Text] [Related]
52. The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture.
Hoh A; Dewerth A; Vogt F; Wenz J; Baeuerle PA; Warmann SW; Fuchs J; Armeanu-Ebinger S
Liver Int; 2013 Jan; 33(1):127-36. PubMed ID: 23088518
[TBL] [Abstract][Full Text] [Related]
53. Regulatory Interactions Between Neutrophils, Tumor Cells and T Cells.
Oberg HH; Wesch D; Kalyan S; Kabelitz D
Front Immunol; 2019; 10():1690. PubMed ID: 31379875
[TBL] [Abstract][Full Text] [Related]
54. γδ T cells in cancer immunotherapy.
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
[TBL] [Abstract][Full Text] [Related]
55. Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.
Beck BH; Kim HG; Kim H; Samuel S; Liu Z; Shrestha R; Haines H; Zinn K; Lopez RD
Breast Cancer Res Treat; 2010 Jul; 122(1):135-44. PubMed ID: 19763820
[TBL] [Abstract][Full Text] [Related]
56. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer.
Liu Z; Eltoum IE; Guo B; Beck BH; Cloud GA; Lopez RD
J Immunol; 2008 May; 180(9):6044-53. PubMed ID: 18424725
[TBL] [Abstract][Full Text] [Related]
57. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.
Miyashita T; Miki K; Kamigaki T; Makino I; Nakagawara H; Tajima H; Takamura H; Kitagawa H; Fushida S; Ahmed AK; Duncan MD; Harmon JW; Ohta T
Clin Exp Med; 2017 Feb; 17(1):19-31. PubMed ID: 26449615
[TBL] [Abstract][Full Text] [Related]
58. ICAM-1 is necessary for epithelial recruitment of gammadelta T cells and efficient corneal wound healing.
Byeseda SE; Burns AR; Dieffenbaugher S; Rumbaut RE; Smith CW; Li Z
Am J Pathol; 2009 Aug; 175(2):571-9. PubMed ID: 19608878
[TBL] [Abstract][Full Text] [Related]
59. Hspa8 and ICAM-1 as damage-induced mediators of γδ T cell activation.
Johnson MD; Otuki MF; Cabrini DA; Rudolph R; Witherden DA; Havran WL
J Leukoc Biol; 2022 Jan; 111(1):135-145. PubMed ID: 33847413
[TBL] [Abstract][Full Text] [Related]
60. Gammadelta T cells: innately adaptive immune cells?
Ferreira LM
Int Rev Immunol; 2013 Jun; 32(3):223-48. PubMed ID: 23617235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
